Answers are grounded in this paper and cite their sources.
This expert opinion reviews the burden of RSV in at-risk adults aged 18-59 years and summarizes available evidence to provide expert considerations that may inform prevention strategies. Adults with comorbidities or immunocompromise frequently experience severe RSV infection, with annual and seasonal rates of 37.6 per 1000 persons/year and 28.4 per 1000 persons/season, respectively. Clinical presentation ranges from being asymptomatic through to acute respiratory distress, with 6.5-32.8% at-risk adults requiring hospitalization for RSV disease. Three preventative vaccines (RSVpreF, mRNA-1345, RSVPreF3) are currently approved in Europe for adults ≥18 years and in the United States for adults ≥60 years and 18-59 years at increased risk. The panel supports RSV vaccination in adults 18-59 years with severe forms of immunocompromise, respiratory disease, cardiovascular disease, neurological/neuromuscular disease, or renal disease. Higher vaccination rates in this population can be achieved by enhancing awareness, empowering health-care professionals, developing consistent policies, and improving access.
No takes yet. Share an insight, caveat, or question.
Andreoni et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: